Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 24/6/2019
SIETES contiene 92761 citas

 
 
<< anterior 21 a 40 de 2091 siguiente >>
Presentar resultados
Seleccionar todas
21. Cita con resumen
Anónimo. UK court rules that NHS can fund HIV PrEP drug. DIA Daily 2016:1. [Ref.ID 100564]
22. Cita con resumen
Anónimo. Loperamide (Imodium): Drug Safety Communication - Serious heart problems with high doses from abuse and misuse. U.S. Food and Drug Administration 2016:7 de junio. [Ref.ID 100377]
24. Cita con resumen
Anónimo. QT interval and drug therapy. Drug Ther Bull 2016;54:33-6. [Ref.ID 100134]
25. Cita con resumen
Anónimo. India adds 28 new drugs to essential medicines list. DIA Daily 2015:28 de diciembre. [Ref.ID 99744]
26. Cita con resumen
Anónimo. Hyponatrémies d'origine médicamenteuse. Prescrire 2015;35:666-71. [Ref.ID 99717]
27.Tiene citas relacionadas Cita con resumen
Anónimo. Darunavir + cobicistat. Prescrire 2015;35:649. [Ref.ID 99709]
28.Tiene citas relacionadas Cita con resumen
Anónimo. Cobicistat. Prescrire 2015;35:648-9. [Ref.ID 99708]
29.Tiene citas relacionadas Cita con resumen
Ko TM, Tsai CY, Chen S-Y, Chen KS, Yu K-H, Chu C-S, Huang CM, Wang CR, Weng C-T, Yu C-L, Hsieh S-C, Tsai J-C, Lai W-T, Tsai W-C, Yin G-D, Ou T-T, Cheng K-H, Yen J-H, Liou T-L, Lin T-H, Chen D-Y, Hsiao P-J, Chen DY, Weng M-Y, Chen Y-M, Chen C-H, Liu F-M, Yen H-W, Lee J-J, Hung S-Y, Luo S-F, Yang Y-H, Chuang H-P, Chou Y-C, Liao H-T, Wang C-W, Huang C-L, Chen P, Wong C-S, Wu J-Y, Chen Y-T, Shen C-Y, for the Taiwan Allopurinol-SCAR Consortium. Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study. BMJ 2015;351:h4848. [Ref.ID 99587]
30.Tiene citas relacionadas Cita con resumen
Li-Wan-Po A. Pharmacogenetics begins to deliver on its promises. BMJ 2015;351:h5042. [Ref.ID 99584]
31.Enlace a cita original Cita con resumen
Wyles DL, Ruane PJ, Sulkowski MS, Dieterich D, Luetkemeyer A, Morgan TR, Sherman KE, Dretler R, Fishbein D, Gathe JC, Henn S, Hinestrosa F, Huynh C, McDonald C, Mills A, Overton ET, Ramgopal M, Rashbaum B, Ray G, Scarsella A, Yozviak J, McPhee F, Liu Z, Hughes E, Yin PD, Noviello S, Ackerman P, for the ALLY-2 Investigators. Daclastavir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015;373:714-25. [Ref.ID 99507]
32.Enlace a cita original Cita con resumen
Naggie S, Cooper C, Saag M, Workowski K, Towner WJ, Marks K, Luetkemeyer A, Baden RP, Sax PE, Gane E, Santana-Bagur J, Stamm LM, Yang JC, German P, Dvory-Sobol H, Ni L, Pang PS, McHutchison JG, Stedman CAM, Morales-Ramirez JO, Bräu N, Jayaweera D, Colson AE, Tebas P, Wong DK, Dieterich D, Sulkowski M, for the ION-4 Investigators. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015;373:705-13. [Ref.ID 99506]
33. Cita con resumen
Sax PE, Wohl D, Yin MT, Post F, DeJesus E, Saag M, Pozniak A, Thompson M, Podzamczer D, Molina JM, Oka S, Koenig E, Trottier B, Andrade-Villanueva J, Crofoot G, Custodio JM, Plummer A, Zhong L, Cao H, Martin H, Callebaut C, Cheng AK, Fordyce MW, McCallister S, GS-US-292-0104/0111 Study Team. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet 2015;385:2606-15. [Ref.ID 99315]
34. Cita con resumen
Overton ET, Chan ES, Brown TT, Tebas P, McComsey GA, Melbourne KM, Napoli A, Hardin WR, Ribaudo HJ. Vitamin D and calcium attenuate bone loss with antiretroviral therapy initiation: a randomized trial. Ann Intern Med 2015;162:815-24. [Ref.ID 99296]
35. Cita con resumen
The INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 2015;373:795-807. [Ref.ID 99275]
36. Cita con resumen
Anónimo. Éfavirenz: suicides. Prescrire 2015;35:105. [Ref.ID 98917]
37.Enlace a cita original
Tseng A, Seet J, Phillips EJ. The evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future. Br J Clin Pharmacol 2015;79:182-94. [Ref.ID 98779]
38. Cita con resumen
Anónimo. Triumeq: a 3-drug combination for HIV. Med Lett Drugs Ther 2015;57:7-8. [Ref.ID 98699]
39. Cita con resumen
Raffi F, Babiker AG, Richert L, Molina J-M, George EC, Antinori A, Arribas JR, Grarup J, Hudson F, Schwimmer C, Saillard J, Wallet C, Jansson PO, Allavena C, Van Leeuwen R, Delfraissy J-F, Vella S, Chêne G, Pozniak A, for the NEAT001/ANRS143 Study Group. Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. Lancet 2014;384:1942-51. [Ref.ID 98452]
40. Cita con resumen
Anónimo. CDC: just 30% of Americans with HIV have it under control. DIA Daily 2014:26 de noviembre. [Ref.ID 98336]
Seleccionar todas
 
<< anterior 21 a 40 de 2091 siguiente >>